CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Pliant Therapeutics Announces PLN-101095 Cancer Study Presentations at SITC 2026

By Public Technologies
  • Pliant Therapeutics will present PLN-101095 research at the Society for Immunotherapy of Cancer meeting in Phoenix on November 6-7, 2026.
  • Research indicates selective integrin targeting improves checkpoint inhibitor anti-tumor responses; plasma biomarkers predict sensitization in patients receiving PLN-101095.
  • The oral drug is enrolling patients in the Phase 1b portion of FORTIFY for advanced solid tumors resistant to checkpoint inhibitors.
  • FORTIFY evaluates PLN-101095 with pembrolizumab for safety, tolerability, pharmacokinetics and preliminary anti-tumor activity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291605PRIMZONEFULLFEED9856372) on October 29, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk